Equities

Immunotech Biopharm Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Immunotech Biopharm Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)2.40
  • Today's Change0.05 / 2.13%
  • Shares traded320.02k
  • 1 Year change-41.34%
  • Beta-0.0913
Data delayed at least 15 minutes, as of Mar 05 2026 07:50 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Immunotech Biopharm Ltd is an investment holding company primarily engaged in the research and development, manufacturing and commercialisation of immune cell products for treatments of cancers. The Company's non-genetically modified cell product pipeline includes Expanded Activated Lymphocytes (EAL) and 6B11-OCIK Injection. The Company's chimeric antigen receptor T (CAR-T) cell product pipeline includes CAR-T-19 Injection, Denocabtagene Ciloleucel Injection and aT19 Injection. The Company's T cell receptor engineered T cell therapy (TCR-T) cell product pipeline includes YT003, YT008 and YT007. The Company mainly conducts its businesses in the domestic market.

  • Revenue in HKD (TTM)0.00
  • Net income in HKD-252.80m
  • Incorporated2018
  • Employees173.00
  • Location
    Immunotech Biopharm Ltd8th Floor, Building 1Guosheng Science and Technology ParkNo.1 Kangding Street, Economic and TechnBeijing ChinaCHN
  • Websitehttps://www.eaal.net/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
JW (Cayman) Therapeutics Co Ltd201.05m-698.60m770.48m292.00--0.7493--3.83-1.68-1.680.48462.470.10461.349.59715,492.90-36.34-35.14-47.41-39.0655.52---347.47-898.771.45-1,808.420.2907---8.99--23.10---32.98--
Brii Biosciences Ltd0.00-424.95m988.50m96.00--0.3505-----0.5838-0.58380.003.910.00----0.00-14.05-49.92-14.09-54.57-------12,750.27----0.003---100.00---190.66---33.13--
Sunho Biologics Inc0.00-92.85m1.00bn128.00--1.84-----0.6152-0.61520.003.470.00----0.00-14.33---15.84----------6.57--0.1242------39.74------
B&K Corp Ltd295.22k-206.56m1.04bn100.00--10.85--3,515.15-1.76-1.760.00250.8127----------------92.34---69,968.59------0.0371---44.70---101.78------
HighTide Therapeutics Inc0.00-329.33m1.09bn57.00--2.74-----0.7284-0.72840.000.69330.00----0.00-49.50---63.55--------------0.2129------59.35------
Wuhan YZY Biopharma Co Ltd164.01m-88.27m1.10bn106.00------6.74-0.4553-0.45530.8461-0.16010.580511.5413.961,451,423.00-31.24---133.35--63.96---53.82--0.9019-24.381.21------49.09------
Kintor Pharmaceutical Ltd12.42m-188.97m1.27bn136.00--4.67--102.35-0.4369-0.43690.02870.5460.019410.661.0673,952.98-29.53-47.72-44.54-55.96-55.12-36.16-1,521.00-8,974.730.4222-33.760.2881------85.36---53.11--
Immunotech Biopharm Ltd0.00-252.80m1.45bn173.00---------0.4517-0.45170.00-0.28780.00----0.00-37.04-36.20-186.73-45.67--------0.0712-6.631.48------44.18--5.95--
ImmuneOnco Biopharmaceuticls Shanghi Inc126.80m-342.37m1.50bn195.00--2.34--11.81-0.8703-0.87030.3221.480.148--3,865.48812,796.10-40.09---51.56-------270.79------0.2236--19,109.59--16.76------
Mabpharm Ltd479.51m-31.08m1.65bn383.00--14.7544.743.44-0.0075-0.00750.11630.02710.42090.46594.051,522,250.00-2.73-19.62-4.02-25.6986.40---6.48-211.590.6906-1.580.7552--196.27--38.89---12.13--
Cloudbreak Pharma Inc78.04m-326.47m1.67bn60.00------21.46-0.3892-0.38920.093-3.07------1,530,235.00-------------418.33------19.44------23.40------
Jiangsu Recbio Technology Co Ltd12.33m-739.64m2.08bn507.00--10.14--168.46-1.55-1.550.02580.42420.006----23,216.49-36.26-31.31-64.03-37.31-----5,990.59--0.2767-100.740.8254------1.67--16.82--
Antengene Corp Ltd95.41m-258.57m2.15bn152.00--2.48--22.50-0.4161-0.41610.15361.280.06191.513.20564,570.70-16.77-48.14-19.52-53.0678.54---271.00-1,460.934.41--0.2346--36.62--45.07--259.46--
Data as of Mar 05 2026. Currency figures normalised to Immunotech Biopharm Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

0.04%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 06 Feb 2026268.00k0.04%
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.